About BridgeBio Oncology Therapeutics Inc.
https://bbotx.comBridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors.
CEO
Eli Wallace
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 6
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
OMEGA FUND MANAGEMENT, LLC
Shares:3.29M
Value:$39.61M
ALPHABET INC.
Shares:2.82M
Value:$33.99M
ENAVATE SCIENCES GP, LLC
Shares:2.63M
Value:$31.63M
Summary
Showing Top 3 of 10
About BridgeBio Oncology Therapeutics Inc.
https://bbotx.comBridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $49.18M ▲ | $-44.76M ▼ | 0% | $-1.9 ▼ | $-49M ▼ |
| Q2-2025 | $0 | $30.09M ▲ | $-28.43M ▼ | 0% | $0.04 ▲ | $-29.91M ▼ |
| Q1-2025 | $0 | $23.14M ▲ | $-22.05M ▼ | 0% | $-0.02 ▼ | $-23.08M ▼ |
| Q4-2024 | $0 | $21.88M ▲ | $-19.69M ▼ | 0% | $0.12 ▲ | $-21.83M ▼ |
| Q3-2024 | $0 | $19.66M | $-17.32M | 0% | $0.1 | $-19.61M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $468.29M ▲ | $484.79M ▲ | $38.09M ▼ | $446.7M ▲ |
| Q2-2025 | $131.4M ▲ | $151.25M ▼ | $378.99M ▲ | $-227.73M ▼ |
| Q1-2025 | $963.13K ▼ | $195.68M ▲ | $7.39M ▲ | $188.29M ▼ |
| Q4-2024 | $1.7M ▼ | $194.42M ▲ | $5.71M ▲ | $188.72M ▲ |
| Q3-2024 | $1.79M | $192.33M | $5.65M | $186.69M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-44.76M ▼ | $-70.63M ▼ | $65.56M ▲ | $383.99M ▲ | $408.08M ▲ | $-71.16M ▼ |
| Q2-2025 | $-28.43M ▼ | $-23.29M ▼ | $9.64M ▲ | $18.96M ▲ | $5.3M ▲ | $-23.52M ▼ |
| Q1-2025 | $-487.39K ▼ | $-734.64K ▼ | $0 | $0 | $-734.64K ▼ | $-734.64K ▼ |
| Q4-2024 | $1.95M ▲ | $-87.86K ▲ | $0 ▼ | $0 ▼ | $-87.86K ▼ | $-87.86K ▲ |
| Q3-2024 | $-17.32M | $-39.34M | $37.91M | $19.78M | $-28.86K | $-39.38M |
CEO
Eli Wallace
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 6
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
OMEGA FUND MANAGEMENT, LLC
Shares:3.29M
Value:$39.61M
ALPHABET INC.
Shares:2.82M
Value:$33.99M
ENAVATE SCIENCES GP, LLC
Shares:2.63M
Value:$31.63M
Summary
Showing Top 3 of 10